Color Vision Tied to Bladder Survival

Patients with impaired color perception may be less likely to recognize blood in urine, potentially delaying diagnosis of cancers that rely on visible bleeding as an early warning sign.

By
Kerri Miller
March 10, 2026
5 min

Conexiant

At a Glance

Category	Detail
Condition	Bladder Cancer with Color Vision Deficiency
Key Mechanisms	Impaired ability to recognize blood in urine may delay diagnosis and treatment.
Target Population	Patients with bladder cancer, particularly those with color vision deficiency.
Care Setting	Oncology and primary care settings.

Key Highlights

Patients with bladder cancer and color vision deficiency had a 52% higher 20-year mortality risk, indicating a need for increased clinical awareness.
No significant survival difference was found in colorectal cancer patients with color vision deficiency.
Color vision deficiency affects approximately 8% of males and 0.5% of females.
Delayed recognition of blood in urine may lead to worse outcomes in bladder cancer.

Guideline-Based Recommendations

Diagnosis

Consider color vision deficiency as a factor in bladder cancer diagnosis.

Management

Monitor patients with bladder cancer for signs of delayed diagnosis due to color vision deficiency, including education on recognizing blood in urine.

Monitoring & Follow-up

Evaluate the need for targeted screening strategies for high-risk patients.

Risks

Increased mortality risk associated with delayed diagnosis in patients with color vision deficiency.

Patient & Prescribing Data

Patients diagnosed with bladder cancer, particularly those with color vision deficiency.

No specific treatment changes recommended; findings are hypothesis-generating.

Clinical Best Practices

Increase suspicion of bladder cancer in patients with color vision deficiency presenting with nonspecific signs.
Consider screening for color vision deficiency in patients with bladder cancer.